|
|
|
| Clinical Efficacy of Perospirone Combined with Olanzapine in the Treatment of Schizophrenia and its Influence on Glucose and Lipid Metabolism |
| SHEN Guiyu, HUANG Yan, HUANG Haidong, et al |
| Baoshan District Mental Health Center, Shanghai 201900 |
|
|
|
|
Abstract 【Objective】To explore the clinical efficacy of perospirone combined with olanzapine in the treatment of schizophrenia and its influence on glucose and lipid metabolism.【Methods】A total of 102 schizophrenia patients admitted to our hospital from November 2020 to December 2023 were selected and divided into the observation group (treated with perospirone combined with olanzapine) and the control group (treated with olanzapine alone) by random number table method, with 51 cases in each group. The clinical efficacy after two months of treatment, symptom scores [Positive and Negative Symptom Scale (PANSS) scores] before and after two months of treatment, glucose and lipid metabolism levels [fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C)], and cognitive function [Wisconsin Card Sorting Test (WCST) scores] were compared between the two groups. 【Results】 The total clinical effective rate of the observation group was 94.12% (48/51), which was higher than 78.43% (40/51) of the control group, and the difference was statistically significant (χ2=5.299, P<0.05). After treatment, the positive symptoms, negative symptoms, and general pathological scores of the two groups were lower than those before treatment, and the observation group was lower than the control group, with statistically significant differences (P<0.05). After treatment, the serum FBG, HbA1c, TC, TG, and LDL-C levels of the two groups were lower than those before treatment, and the observation group was lower than the control group, with statistically significant differences (P<0.05). After treatment, the number of completed classifications and total correct scores of the two groups were higher than those before treatment, and the observation group was higher than the control group, with statistically significant differences (P<0.05); the total response number, persistent error number, and total error scores of the two groups were lower than those before treatment, and the observation group was lower than the control group, with statistically significant differences (P<0.05). 【Conclusion】Perospirone combined with olanzapine can effectively improve the clinical efficacy of schizophrenia patients, ameliorate their psychiatric symptoms, effectively regulate glucose and lipid metabolism levels, and help improve patients' cognitive function.
|
|
Received: 26 February 2024
|
|
|
|
|
|
[1] 孙亮,刘志伟,张雨龙,等. 伴抑郁的稳定期精神分裂症患者细胞因子水平变化及其影响因素研究[J].中国全科医学,2023,26(6):687-691.
[2] 郑芸,陈方斌,张李婉,等. 定坤丹联合阿立哌唑治疗精神分裂患者因服用抗精神病药物致闭经的疗效观察[J].海军医学杂志,2021,42(6):774-776.
[3] 陈彩红,张伟宏,顾文谊. 奥氮平联合利培酮治疗伴激越症状的精神分裂症的临床观察[J].贵州医药,2023,47(3):360-361.
[4] 朱晓晨,陈彦瑾,韩晟. 哌罗匹隆治疗精神分裂症的药物经济学评价:基于主要不良事件的研究[J].中国药房,2021,32(10):1252-1256.
[5] 第3版《中国精神分裂症防治指南》编写组.第3版《中国精神分裂症防治指南》计划书[J].中华精神科杂志,2023,56(5):331.
[6] 汪卫东,刘寰忠,李文正,等. 精神分裂症患者发病前后饮酒行为与阳性和阴性症状量表评分的关联性研究[J].中国全科医学,2020,23(20):2514-2519.
[7] 杨晓冬,钟文,欧双余,等. 首发精神分裂症患者血清高同型半胱氨酸水平与其认知功能损害的相关性[J].国际精神病学杂志,2023,50(4):643-646.
[8] 吴江,龚士虎,孙洁. 佐匹克隆与氯硝西泮治疗精神分裂症伴睡眠障碍的效果比较[J].河北医科大学学报,2023,44(9):1017.
[9] 李美花,张素娟. 二甲双胍治疗奥氮平致精神分裂症患者代谢综合征的疗效观察[J].中国现代医学杂志,2021,31(2):82-86.
[10] 汪剑,赵勇,何江丽,等. 阿立哌唑与奥氮平治疗首发精神分裂症的疗效及对催乳素水平的影响[J].国际精神病学杂志,2023,50(4):655-658.
[11] 商月骄. 帕利哌酮缓释片与盐酸哌罗匹隆片治疗精神分裂症患者临床疗效观察[J].国际精神病学杂志,2022,49(2):256-258.
[12] 李清梅. 哌罗匹隆联合奥氮平治疗精神分裂症的有效性及安全性[J].临床合理用药,2023,30(16):65-68.
[13] 尹洪海. 盐酸哌罗匹隆、氯氮平联合对缩短慢性精神分裂症病程的影响[J].世界复合医学,2021,7(11):178-181.
[14] 栗永刚. 不同剂量氨磺必利联合盐酸哌罗匹隆对难治性精神分裂症患者糖脂代谢的影响[J].国际精神病学杂志,2022,49(3):433-435.
|
|
|
|
2025, Vol. 42 
